Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03736447 · ClinicalTrials.gov registry record · Phase 3
Peanut Oral Immunotherapy Study of Early Intervention for Desensitization
A Phase 3 study, sponsored by Aimmune Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 146
- Enrollment target
NCT03736447 is a Phase 3 study that has completed, run by Aimmune Therapeutics. The registered enrollment target is 146 participants.
The verdict
NCT03736447, a Phase 3 study, has completed, sponsored by Aimmune Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 146 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of AR101 in peanut-allergic children aged 1 to \< 4 years.
Interventions
- BIOLOGICAL AR101 powder provided in capsules & sachets
- BIOLOGICAL Placebo powder provided in capsules & sachets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2018-12-27 |
| Est. Completion | 2022-07-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03736447
The ClinicalTrials.gov registry entry for NCT03736447 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aimmune Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AR101 powder provided in capsules & sachets is the first listed.
NCT03736447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03736447 about?
NCT03736447 is a clinical study titled "Peanut Oral Immunotherapy Study of Early Intervention for Desensitization". The purpose of this study is to determine the efficacy and safety of AR101 in peanut-allergic children aged 1 to \< 4 years.
What is the current status of trial NCT03736447?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 146 participants. The study started on 2018-12-27. Estimated completion is 2022-07-05.
What interventions are being tested in trial NCT03736447?
The interventions under investigation include: AR101 powder provided in capsules & sachets (BIOLOGICAL), Placebo powder provided in capsules & sachets (BIOLOGICAL).
Who is sponsoring clinical trial NCT03736447?
This trial is sponsored by Aimmune Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.